Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1

Journal of Heart and Lung Transplantation

Volumn 31, Issue 8, 2012, Pages 811-816

  Frantz, Robert P ^a   McDevitt, Susanne ^b   Walker, Susan ^b  

^a MAYO CLINIC   (United States)

^b UNITED THERAPEUTICS CORPORATION   (United States)

Author keywords

6 minute walk distance; biomarker; inhaled treprostinil; N terminal pro B type natriuretic peptide; pulmonary arterial hypertension

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; PLACEBO; SILDENAFIL; UNIPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; WALKING; YOUNG ADULT;

EID: 84863320780     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2012.04.005     Document Type: Article

References (19)

1. S.L. Archer, E.K. Weir, M.R. Wilkins The basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies Circulation 121 2010 2045 2066
2. V.V. McLaughlin, S.L. Archer, D.B. Badesch ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation 119 2009 2250 2294
3. ATS statement: guidelines for the six-minute walk test Am J Respir Crit Care Med 166 2002 111 117
4. A. Peacock, A. Keogh, M. Humbert Endpoints in pulmonary arterial hypertension: the role of clinical worsening Curr Opin Pulm Med 16 suppl 1 2010 S1 S9
5. N.S. Hill, I.R. Preston, K.E. Roberts Patients with pulmonary arterial hypertension in clinical trials: who are they? Proc Am Thorac Soc 5 2008 603 609
6. V.V. McLaughlin, R.L. Benza, L.J. Rubin Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial J Am Coll Cardiol 55 2010 1915 1922
7. A. Fijalkowska, M. Kurzyna, A. Torbicki Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension Chest 129 2006 1313 1321
8. S.C. Mathai, M. Bueso, L.K. Hummers Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension Eur Respir J 35 2010 95 104
9. S.-H. Tsai, Y.-Y. Lin, S.-J. Chu Interpretation and use of natriuretic peptides in non-congestive heart failure settings Yonsei Med J 51 2010 151 163
10. R. Pfister, M. Scholz, K. Wielckens Use of NT-proBNP in routine testing and comparison to BNP Eur J Heart Fail 6 2004 289 293
11. R.L. Benza, D.P. Miller, M. Gomberg-Maitland Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) Circulation 122 2010 164 172
12. V.V. McLaughlin, R.J. Oudiz, A. Frost Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Am J Respir Crit Care Med 174 2006 1257 1263
13. G. Simonneau, L.J. Rubin, N. Galiè Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530
14. R.L. Benza, W. Seeger, V.V. McLaughlin Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension J Heart Lung Transplant 30 2011 1327 1333
15. R.J. Oudiz, N. Galiè, H. Olschewski Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension J Am Coll Cardiol 54 2009 1971 1981
16. L.J. Rubin, D.B. Badesch, T.R. Fleming Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study Chest 140 2011 1274 1283
17. B. Sztrymf, R. Souza, L. Bertoletti Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension Eur Respir J 35 2010 1286 1293
18. N. Galiè, H. Olschewski, R.J. Oudiz Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) group Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
19. H. Gupta, G. Ghimire, R. Naeije The value of tools to assess pulmonary arterial hypertension Eur Respir Rev 20 2011 222 235